In-licensing of NS-73 and NS-87
First written in FY2017. 15 of 24 entries say "Restated". Latest entry: FY2025-H1.
The whole theme swung hardest in 2025: 1 of 12 companies on the "Worse" side.
11 other companies' latest entry also says "Advanced".
- FY2025-H1AdvancedAnnual report
「In the pharmaceuticals business, despite the impact of drug price revisions and generic products, sales of Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, royalty income from overseas sales of the product, and Viltepso, a treatment for Duchenne muscular dystrophy, among others, increased. In addition, Vyxeos, a treatment for high-risk acute myeloid leukemia launched in May, and other products contributed to revenue of ¥68.496 billion, up 12.3% from the same period of the previous year.」
Vyxeos, a treatment for high-risk acute myeloid leukemia corresponding to NS-87, was launched in May and contributed to increased revenue in the pharmaceutical business. - FY2024AchievedAnnual report
「NS-87 (generic names: daunorubicin/cytarabine), a treatment for high-risk acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in March 2017, submitted for regulatory approval in June 2023, and received approval in March 2024.」
NS-87 progressed from the regulatory submission in June 2023 and received approval in March 2024. - FY2024-Q3RestatedAnnual report
「NS-87 (generic names: daunorubicin/cytarabine), a treatment for high-risk acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in 2017, underwent a Phase 1/2 trial beginning in August 2019, and was submitted for regulatory approval in June 2023.」
The company restated that, following its in-licensing, NS-87 underwent a Phase 1/2 trial and was submitted for regulatory approval in June 2023. - FY2024-Q2RestatedAnnual report
「NS-87 (generic names: daunorubicin/cytarabine), a treatment for high-risk acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in 2017, underwent a Phase 1/2 trial beginning in August 2019, and was submitted for regulatory approval in June 2023.」
The company restated that NS-87 was undergoing a Phase 1/2 trial that began in August 2019 and was submitted for regulatory approval in June 2023. - FY2024-Q1AdvancedAnnual report
「NS-87 (generic names: daunorubicin/cytarabine), a treatment for high-risk acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in 2017, underwent a Phase 1/2 trial beginning in August 2019, and was submitted for regulatory approval in June 2023.」
NS-87 progressed from the Phase 1/2 trial stage to the regulatory submission stage in June 2023. - FY2023RestatedAnnual report
「NS-87 (generic names: daunorubicin/cytarabine), a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in 2017 and has been undergoing a Phase 1/2 trial since August 2019.」
The company continues the in-licensing of NS-87 and the Phase 1/2 trial that began in August 2019. - FY2023-Q2RestatedAnnual report
「NS-87 (generic names: daunorubicin/cytarabine), a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in 2017 and has been undergoing a Phase 1/2 trial since August 2019.」
The company continues the in-licensing of NS-87 and the Phase 1/2 trial that began in August 2019. - FY2022-Q3RestatedAnnual report
「NS-87 (generic names: daunorubicin/cytarabine), a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in 2017 and has been undergoing a Phase 1/2 trial since August 2019.」
The company continues the in-licensing of NS-87 and the Phase 1/2 trial that began in August 2019. - FY2022-Q2RestatedAnnual report
「NS-87 (generic names: daunorubicin/cytarabine), a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in 2017 and has been undergoing a Phase 1/2 trial since August 2019.」
The company continues the in-licensing of NS-87 and the Phase 1/2 trial that began in August 2019. - FY2022-Q1RestatedAnnual report
「NS-87, a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in 2017 and has been undergoing a Phase 1/2 trial since August 2019.」
The company continues the in-licensing of NS-87 and the Phase 1/2 trial that began in August 2019. - FY2021RestatedAnnual report
「NS-87, a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals (Ireland) in 2017 and has been undergoing a Phase 1/2 trial since August 2019.」
The company continues the in-licensing of NS-87 and the Phase 1/2 trial that began in August 2019. - FY2021-Q3RestatedAnnual report
「NS-87, a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals in 2017, and a Phase 1/2 trial began in August 2019.」
NS-87 continues its Phase 1/2 trial that began in August 2019. - FY2021-Q2RestatedAnnual report
「NS-87, a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals in 2017, and a Phase 1/2 trial began in August 2019.」
NS-87 continues its Phase 1/2 trial that began in August 2019. - FY2021-Q1RestatedAnnual report
「NS-87, a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals in 2017, and a Phase 1/2 trial began in August 2019.」
NS-87 continues its Phase 1/2 trial that began in August 2019. - FY2020-Q3RestatedAnnual report
「NS-73 (generic name: defibrotide sodium), a treatment for sinusoidal obstruction syndrome (SOS), was in-licensed from Jazz Pharmaceuticals (Ireland) in March 2017, designated by the Ministry of Health, Labour and Welfare as an orphan drug in May 2019, and launched in September 2019. In addition, in June 2018, the company began a Phase 3 trial for the prevention of SOS jointly with Jazz Pharmaceuticals. NS-87, a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals in March 2017, and a Phase 1/2 trial began in August 2019.」
Following the launch of NS-73, the company continued the Phase 3 trial for SOS prevention, while NS-87 continued its Phase 1/2 trial that began in August 2019. - FY2020-Q2AdvancedAnnual report
「NS-73 (generic name: defibrotide sodium), a treatment for sinusoidal obstruction syndrome (SOS), was in-licensed from Jazz Pharmaceuticals (Ireland) in March 2017, designated by the Ministry of Health, Labour and Welfare as an orphan drug in May of the current year, and launched in September of the current year. In addition, in June of the previous year, the company began a Phase 3 trial for the prevention of SOS jointly with Jazz Pharmaceuticals. NS-87, a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals in March 2017, and a Phase 1/2 trial began in August of the current year.」
NS-73 progressed from approval to the launch stage in September. NS-87 also progressed from the development preparation stage to the start of Phase 1/2 trials. - FY2020-Q1AdvancedAnnual report
「NS-73 (generic name: defibrotide sodium), a treatment for sinusoidal obstruction syndrome (SOS) and hepatic veno-occlusive disease (VOD), was in-licensed from Jazz Pharmaceuticals (Ireland) in March 2017, designated by the Ministry of Health, Labour and Welfare as an orphan drug in September of the previous year, and approved in June of the current year. In addition, in June of the previous year, the company began a Phase 3 trial for the prevention of SOS/VOD jointly with Jazz Pharmaceuticals.」
NS-73 progressed from the regulatory submission preparation stage to approval in June of the current year, and the Phase 3 trial for the prevention of SOS/VOD continued. NS-87 was separately described as being in preparation for Phase 1/2 trials. - FY2019-Q3RestatedAnnual report
「NS-73 (generic name: defibrotide sodium), a treatment for hepatic veno-occlusive disease (VOD), was in-licensed from Jazz Pharmaceuticals (Ireland) in March 2017, designated by the Ministry of Health, Labour and Welfare as an orphan drug in September of the previous year, and submitted for regulatory approval on 17 October of the previous year. In addition, in June of the previous year, the company began a Phase 3 trial for the prevention of VOD jointly with Jazz Pharmaceuticals. NS-87, a treatment for secondary acute myeloid leukemia, was in-licensed from Jazz Pharmaceuticals in March 2017 and is currently in development preparation.」
Following the regulatory submission for NS-73, the company continued the Phase 3 trial for VOD prevention, while NS-87 remained in development preparation. - FY2019-Q2AdvancedAnnual report
「NS-73 (generic name: defibrotide sodium), a treatment for hepatic veno-occlusive disease (VOD), was in-licensed from Jazz Pharmaceuticals (Ireland) in March of the previous year, and the company submitted an application for regulatory approval on 17 October of the current year. In addition, in June of the current year, the company began a Phase 3 trial for the prevention of VOD jointly with Jazz Pharmaceuticals.」
NS-73 progressed from the regulatory submission preparation stage and an application for approval was filed on 17 October 2018. A Phase 3 trial for the prevention of VOD was also started jointly. NS-87 remained in development preparation. - FY2019-Q1AdvancedAnnual report
「NS-73 (generic name: defibrotide sodium), a treatment for hepatic veno-occlusive disease, was in-licensed from Jazz Pharmaceuticals (Ireland) in March of the previous year and is currently in preparation for regulatory submission. In addition, in June of the current year, the company began a Phase 3 trial for the prevention of hepatic veno-occlusive disease jointly with Jazz Pharmaceuticals.」
In addition to preparing the regulatory submission for NS-73 following its in-licensing, the company began a Phase 3 trial for the prevention of hepatic veno-occlusive disease jointly with Jazz Pharmaceuticals in June of the current year. - FY2018-Q3AdvancedAnnual report
「NS-73, a treatment for hepatic veno-occlusive disease, was in-licensed from Jazz Pharmaceuticals (Ireland) in March 2017 and is currently in preparation for regulatory submission.」
NS-73 progressed from the development preparation stage following its in-licensing to the regulatory submission preparation stage. NS-87 was still described as being in development preparation. - FY2018-Q2RestatedAnnual report
「NS-73, a treatment for hepatic veno-occlusive disease, and NS-87, a treatment for secondary acute myeloid leukemia, were in-licensed from Jazz Pharmaceuticals (Ireland) in March 2017 and are currently in development preparation.」
The company restated that NS-73 and NS-87 remain in the development preparation stage following their in-licensing. - FY2018-Q1RestatedAnnual report
「NS-73, a treatment for hepatic veno-occlusive disease, and NS-87, a treatment for secondary acute myeloid leukemia, were in-licensed from Jazz Pharmaceuticals (Ireland) in March 2017 and are currently in development preparation.」
The company restated that NS-73 and NS-87 remain in the development preparation stage following their in-licensing. - FY2017First statedAnnual report
「In March 2017, the company in-licensed NS-73, a treatment for hepatic veno-occlusive disease, and NS-87, a treatment for secondary acute myeloid leukemia, from Jazz Pharmaceuticals (Ireland).」
The company in-licensed a treatment for hepatic veno-occlusive disease and a treatment for secondary acute myeloid leukemia from Jazz Pharmaceuticals.